SWOT Analysis for Mankind Pharma Ltd. - Strengths

Add SWOT widget to your site/app

Benjamin Graham Value Screen

Expensive Performers (DVM)

PEG lower than Industry PEG

Relative Outperformance versus Industry over 1 Week

Increasing profits every quarter for the past 2 quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Promoter decreasing their shareholding

MACD Crossover Below Signal Line

PE higher than Industry PE

High PE (PE > 40)

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Declining Net Cash Flow : Companies not able to generate net cash

Weak Momentum: Price below Short, Medium and Long Term Averages

RSI indicating price weakness

MACD crossed below zero line previous end of day

MACD crossed below signal line previous end of day

Top Losers

Declining profitability: Falling ROCE

Stocks Underperforming their Industry Price Change in the Quarter

Broker price or reco upgrades in last month

Brokers upgraded recommendation or target price in the past three months

Broker Upgrades: Stocks where brokers upgraded recommendation or price target in the past one month

FII / FPI or Institutions increasing their shareholding

Broker price or reco upgrades in last month

Mutual Funds Increased Shareholding over the Past Two Months

Companies with high market cap, lower public shareholding

MFs decreased their shareholding last quarter

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks